ATE339417T1 - Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten - Google Patents
Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonistenInfo
- Publication number
- ATE339417T1 ATE339417T1 AT00984282T AT00984282T ATE339417T1 AT E339417 T1 ATE339417 T1 AT E339417T1 AT 00984282 T AT00984282 T AT 00984282T AT 00984282 T AT00984282 T AT 00984282T AT E339417 T1 ATE339417 T1 AT E339417T1
- Authority
- AT
- Austria
- Prior art keywords
- endothelin
- sulfonamide
- antagonists
- biphenyl
- receptor
- Prior art date
Links
- SBXDENYROQKXBE-UHFFFAOYSA-N 2-phenylbenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1C1=CC=CC=C1 SBXDENYROQKXBE-UHFFFAOYSA-N 0.000 title 1
- 102000015427 Angiotensins Human genes 0.000 title 1
- 108010064733 Angiotensins Proteins 0.000 title 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title 1
- 230000009977 dual effect Effects 0.000 title 1
- 239000002308 endothelin receptor antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C07D261/16—Benzene-sulfonamido isoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46403799A | 1999-12-15 | 1999-12-15 | |
| US48119700A | 2000-01-11 | 2000-01-11 | |
| US51377900A | 2000-02-25 | 2000-02-25 | |
| US60432200A | 2000-06-26 | 2000-06-26 | |
| US64364000A | 2000-08-22 | 2000-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339417T1 true ATE339417T1 (de) | 2006-10-15 |
Family
ID=27541688
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00984282T ATE339417T1 (de) | 1999-12-15 | 2000-12-13 | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1237888B1 (de) |
| JP (1) | JP2003520785A (de) |
| AR (1) | AR029417A1 (de) |
| AT (1) | ATE339417T1 (de) |
| AU (1) | AU2092601A (de) |
| CA (1) | CA2395088A1 (de) |
| CO (1) | CO5450242A1 (de) |
| DE (1) | DE60030764T2 (de) |
| ES (1) | ES2273739T3 (de) |
| PE (1) | PE20010930A1 (de) |
| UY (1) | UY26482A1 (de) |
| WO (1) | WO2001044239A2 (de) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6639082B2 (en) | 2000-10-17 | 2003-10-28 | Bristol-Myers Squibb Company | Methods for the preparation of biphenyl isoxazole sulfonamides |
| US7067539B2 (en) | 2001-02-08 | 2006-06-27 | Schering Corporation | Cannabinoid receptor ligands |
| US7507767B2 (en) | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
| WO2002096883A1 (en) | 2001-05-31 | 2002-12-05 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| CA2466440A1 (en) | 2001-11-14 | 2003-05-22 | Schering Corporation | Cannabinoid receptor ligands |
| US6984645B2 (en) | 2001-11-16 | 2006-01-10 | Bristol-Myers Squibb Company | Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein |
| TWI328007B (en) | 2002-01-16 | 2010-08-01 | Astrazeneca Ab | Novel compounds |
| EP1539693B9 (de) | 2002-06-19 | 2008-10-08 | Schering Corporation | Agonisten des cannabinoidrezeptors |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| WO2004085420A1 (en) * | 2003-03-24 | 2004-10-07 | Vicore Pharma Ab | Bicyclic compounds useful as angiotensin ii agonists |
| EP1660183A2 (de) * | 2003-05-05 | 2006-05-31 | Eli Lilly and Company | Behandlung von kardiovaskulären erkrankungen mit einer substanz der formel 1 (cs 747 - prasugrel, rn 150322-43-4) |
| DE10336497B4 (de) * | 2003-08-08 | 2007-04-05 | Freie Universität Berlin | Substituierte Pyridine und ein Verfahren zur Herstellung von substituierten Pyridinen |
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| EP2650011A1 (de) * | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Verfahren zur Behandlung oder Prophylaxe |
| CN101437818A (zh) * | 2006-03-03 | 2009-05-20 | 托伦特药物有限公司 | At1和eta受体的新的双重作用受体拮抗剂(dara) |
| WO2007109456A2 (en) * | 2006-03-16 | 2007-09-27 | Pharmacopeia, Inc. | Substituted biphenyl isoxazole sulfonamides as dual angiotensin endothelin receptor antagonists |
| AU2012203919B2 (en) * | 2006-03-20 | 2014-10-23 | Novartis Ag | Method of treatment or prophylaxis of inflammatory pain |
| JP5230595B2 (ja) | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | 炎症性疼痛の治療または予防の方法 |
| MX2009006228A (es) | 2006-12-12 | 2009-06-22 | Schering Corp | Inhibidores de aspartil proteasa. |
| TW200838501A (en) * | 2007-02-02 | 2008-10-01 | Theravance Inc | Dual-acting antihypertensive agents |
| WO2009155448A1 (en) * | 2008-06-20 | 2009-12-23 | Ligand Pharmaceuticals Inc. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| WO2009158309A2 (en) * | 2008-06-25 | 2009-12-30 | Ligand Pharmaceuticals Inc. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| GB0815947D0 (en) * | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| JP2012522058A (ja) | 2009-03-31 | 2012-09-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンｉｉ受容体アゴニストの経口製剤 |
| US7956054B2 (en) * | 2009-07-07 | 2011-06-07 | Theravance, Inc. | Dual-acting pyrazole antihypertensive agents |
| CN104761548B (zh) * | 2015-04-27 | 2017-09-12 | 梯尔希（南京）药物研发有限公司 | 一种稳定同位素标记的二苯基磺酰胺类药物的制备方法 |
| KR20230066644A (ko) | 2016-10-13 | 2023-05-16 | 트래비어 테라퓨틱스, 인코포레이티드 | 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 |
| US10703723B2 (en) | 2017-03-09 | 2020-07-07 | Truly Translational Sweden Ab | Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease |
| WO2018220101A1 (en) | 2017-05-31 | 2018-12-06 | Truly Translational Sweden Ab | A pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy |
| WO2019065794A1 (ja) * | 2017-09-27 | 2019-04-04 | 国立大学法人鹿児島大学 | Ｐａｃ１受容体拮抗薬を用いた鎮痛薬 |
| FI3488868T3 (fi) | 2017-11-23 | 2023-10-20 | Medac Ges Fuer Klinische Spezialpraeparate Mbh | Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö |
| EP3489222A1 (de) | 2017-11-23 | 2019-05-29 | medac Gesellschaft für klinische Spezialpräparate mbH | Sulfasalazinesalze, herstellungsverfahren und verwendungen |
| KR102902972B1 (ko) | 2018-10-04 | 2025-12-22 | 트래버르 테라퓨틱스, 인코포레이티드 | Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물 |
| MA54542A (fr) * | 2018-12-21 | 2021-10-27 | Travere Therapeutics Inc | Compositions de sparsentan amorphe |
| CN109928897B (zh) * | 2019-04-01 | 2021-09-14 | 四川大学华西医院 | 防治梗死性疾病的双胍衍生物及其应用 |
| WO2022266370A1 (en) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan for treating idiopathic pulmonary fibrosis |
| WO2023025277A1 (zh) * | 2021-08-26 | 2023-03-02 | 上海翰森生物医药科技有限公司 | 含芳环类生物拮抗剂、其制备方法和应用 |
| EP4421073A4 (de) * | 2021-10-21 | 2025-02-26 | Nicoya Therapeutics (Shanghai) Co., Ltd | Dualer antagonisten und verwendung davon |
| AR128112A1 (es) * | 2021-12-28 | 2024-03-27 | Alchemedicine Inc | Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica |
| CN115636799A (zh) * | 2022-11-04 | 2023-01-24 | 苏州莱安医药化学技术有限公司 | 一种双效内皮素-血管紧张素受体拮抗剂的制备方法 |
| AU2024224496A1 (en) * | 2023-02-24 | 2025-10-02 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Salt containing aromatic ring derivative antagonist, preparation method therefor, and application thereof |
| IT202400000246A1 (it) | 2024-01-09 | 2025-07-09 | Procos Spa | Processo per la preparazione di sparsentan |
| CN120289447A (zh) * | 2025-06-11 | 2025-07-11 | 成都臻拓医药科技有限公司 | 一种司帕生坦的晶型及其制备方法、药物组合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260328A (en) * | 1989-04-06 | 1993-11-09 | Farmitalia Carlo Erba Srl | Phenyl-indenopurazol 3-oxo-propanamide derivatives useful in the treatment of rheumatoid arthritis |
| PH30484A (en) * | 1990-02-19 | 1997-05-28 | Ciba Geigy | Acy compounds pharmaceutical composition containing said compound and method of use thereof |
| US5260325A (en) * | 1991-08-19 | 1993-11-09 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking tertiary amides |
| GB2264710A (en) * | 1992-03-04 | 1993-09-08 | Merck & Co Inc | Quinoline and azaquinoline angiotensin ii antagonists incorporating a substituted biphenyl element |
| NZ247440A (en) * | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5514696A (en) * | 1992-05-06 | 1996-05-07 | Bristol-Myers Squibb Co. | Phenyl sulfonamide endothelin antagonists |
| WO1994002142A1 (en) * | 1992-07-17 | 1994-02-03 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| US5780473A (en) * | 1995-02-06 | 1998-07-14 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| US5760038A (en) * | 1995-02-06 | 1998-06-02 | Bristol-Myers Squibb Company | Substituted biphenyl sulfonamide endothelin antagonists |
| AU6108596A (en) * | 1995-06-15 | 1997-01-15 | Merck & Co., Inc. | Polymorphic forms of an angiotensin ii antagonist |
| GB9512697D0 (en) * | 1995-06-22 | 1995-08-23 | Zeneca Ltd | Heterocyclic compounds |
| US5846990A (en) * | 1995-07-24 | 1998-12-08 | Bristol-Myers Squibb Co. | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| PT1094816E (pt) * | 1998-07-06 | 2009-03-10 | Bristol Myers Squibb Co | Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina |
-
2000
- 2000-12-13 CA CA002395088A patent/CA2395088A1/en not_active Abandoned
- 2000-12-13 EP EP00984282A patent/EP1237888B1/de not_active Expired - Lifetime
- 2000-12-13 DE DE60030764T patent/DE60030764T2/de not_active Expired - Fee Related
- 2000-12-13 AT AT00984282T patent/ATE339417T1/de not_active IP Right Cessation
- 2000-12-13 JP JP2001544729A patent/JP2003520785A/ja not_active Withdrawn
- 2000-12-13 EP EP06016968A patent/EP1741713A3/de not_active Withdrawn
- 2000-12-13 AU AU20926/01A patent/AU2092601A/en not_active Abandoned
- 2000-12-13 WO PCT/US2000/033730 patent/WO2001044239A2/en not_active Ceased
- 2000-12-13 ES ES00984282T patent/ES2273739T3/es not_active Expired - Lifetime
- 2000-12-14 CO CO00095238A patent/CO5450242A1/es not_active Application Discontinuation
- 2000-12-14 UY UY26482A patent/UY26482A1/es not_active Application Discontinuation
- 2000-12-15 AR ARP000106686A patent/AR029417A1/es unknown
- 2000-12-15 PE PE2000001349A patent/PE20010930A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2273739T3 (es) | 2007-05-16 |
| EP1237888B1 (de) | 2006-09-13 |
| UY26482A1 (es) | 2001-07-31 |
| JP2003520785A (ja) | 2003-07-08 |
| AR029417A1 (es) | 2003-06-25 |
| EP1741713A2 (de) | 2007-01-10 |
| CA2395088A1 (en) | 2001-06-21 |
| WO2001044239A3 (en) | 2001-11-01 |
| DE60030764D1 (de) | 2006-10-26 |
| AU2092601A (en) | 2001-06-25 |
| DE60030764T2 (de) | 2007-09-13 |
| EP1741713A3 (de) | 2009-09-09 |
| WO2001044239A2 (en) | 2001-06-21 |
| EP1237888A2 (de) | 2002-09-11 |
| PE20010930A1 (es) | 2001-11-18 |
| CO5450242A1 (es) | 2004-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60030764D1 (de) | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten | |
| NO20016115D0 (no) | Substituerte heterocykelkondenserte gamma-karboliner | |
| PT1224180E (pt) | Azois substituidos | |
| DE60044373D1 (de) | Durchflusszytometerprobenbehandlungsverfahren | |
| DE60008674D1 (de) | Funkwegführungssystem | |
| DE60002992D1 (de) | Dreiphasenabscheider | |
| DE60005976D1 (de) | Speicherkkarte | |
| SE0002096A0 (sv) | Avgasrecirkuleringssystem | |
| DE60134094D1 (de) | C7-taxanester als antitumormittel | |
| DE69932949D1 (de) | Aufszugssteuerung | |
| DE60016396D1 (de) | Foerdervorrichtung | |
| DE60034061D1 (de) | 4-pyrimidinyl-n-acyl-l-phenylanine | |
| DE60001894T2 (de) | Busschienenverbindungsstruktur | |
| DE50015451D1 (de) | Spülwannensystem | |
| DE60012888D1 (de) | Mevinolinderivate | |
| DE60036617D1 (de) | Monofluoralkylderivate | |
| DE50011908D1 (de) | 16-hydroxyestratriene als selektiv wirksame estrogene | |
| DE69924240D1 (de) | Ladungsträgerteilchenstrahlvorrichtung | |
| DE60013054D1 (de) | Reissverschlusszuglasche | |
| DE60022878D1 (de) | Konzentrizitätsring | |
| DE60043569D1 (de) | Elektrodenherstellverfahren | |
| DE60003072D1 (de) | Thiazolidindion-derivate als antidiabetika | |
| DE60013707D1 (de) | Flüssigkeitsdosierventil | |
| NO20022927L (no) | Substituerte pyrrazoler | |
| DE60019673D1 (de) | Metallpulverspritzgiesszusammensetzung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |